Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: yokoyama t. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F. Hata A, et al. Among authors: yokoyama t. Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7. Cancer. 2018. PMID: 30192383 Free article. Clinical Trial.
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: yokoyama t. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, Tanizaki J, Tanaka K, Takeda M, Ogura T, Ishida T, Ito A, Nakagawa K. Isomoto K, et al. Among authors: yokoyama t. Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937613
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K. Takahama T, et al. Among authors: yokoyama t. Cancer. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5. Cancer. 2020. PMID: 32022929 Free article. Clinical Trial.
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Yamanaka T, Okamoto H. Ikeda S, et al. Among authors: yokoyama t. J Thorac Oncol. 2020 Dec;15(12):1935-1942. doi: 10.1016/j.jtho.2020.08.018. Epub 2020 Aug 25. J Thorac Oncol. 2020. PMID: 32858235 Free PMC article. Clinical Trial.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Hayashi H, Ogura M, Niwa T, Yokoyama T, Tanizaki J, Ozaki T, Yoshioka H, Kurata T, Tamura Y, Fujisaka Y, Tanaka K, Hasegawa Y, Kudo K, Chiba Y, Nakagawa K. Hayashi H, et al. Among authors: yokoyama t. Oncologist. 2021 Jan;26(1):19-e52. doi: 10.1002/ONCO.13524. Epub 2020 Sep 28. Oncologist. 2021. PMID: 32918791 Free PMC article. Clinical Trial.
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, Daga H, Okamoto I, Akamatsu H, Teraoka S, Ono A, Ohira T, Yokoyama T, Yamamoto N, Nakagawa K, Nishio K. Sakai K, et al. Among authors: yokoyama t. Mol Oncol. 2021 Jan;15(1):126-137. doi: 10.1002/1878-0261.12841. Epub 2020 Nov 17. Mol Oncol. 2021. PMID: 33131198 Free PMC article. Clinical Trial.
3,828 results